markets · · businesswire.com

AL-S Pharma Appoints Harry Welten as Chief Executive Officer

ZURICH, Switzerland--(BUSINESS WIRE)--AL-S Pharma AG (“AL-S Pharma” or “the Company”), a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the appointment of Harry Welten as chief executive officer (CEO). Mr. Welten succeeds Michael Salzmann, Ph.D. The Company recently reported positive topline results from a Phase 2 study of its lead program AP-101, a human monoclonal.

AL-S Pharma Appoints Harry Welten as Chief Executive Officer

ZURICH, Switzerland--(BUSINESS WIRE)--AL-S Pharma AG (“AL-S Pharma” or “the Company”), a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the appointment of Harry Welten as chief executive officer (CEO). Mr. Welten succeeds Michael Salzmann, Ph.D. The Company recently reported positive topline results from a Phase 2 study of its lead program AP-101, a human monoclonal.

  • #STOCK